GlassScriptPhysician profile
Stephen H Phillips
NPI 1508123407
$5,397.89
in general payments reported to CMS, 2019-2025
32 companies · $868 in 2025
The $868 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $478 · 2021: $387 · 2022: $727 · 2023: $1,212 · 2024: $1,016 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,068 · Education: $28.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,067.53 |
| Education | $28.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,320.20 | 2019-2025 | Xtandi, Myrbetriq |
| Abbvie INC. | $840.05 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $587.77 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $454.38 | 2019-2024 | Erleada, Akeega, Balversa |
| Endo Pharmaceuticals INC. | $252.97 | 2019-2024 | Aveed, Xiaflex |
| C. R. Bard, INC. & Subsidiaries | $230.78 | 2019-2025 | Bard Urinary Drainage Bag |
| Urogen Pharma, INC. | $219.97 | 2023-2025 | Jelmyto |
| Endo USA, INC. | $204.85 | 2024-2025 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $188.21 | 2024-2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $152.30 | 2019-2025 | |
| Pfizer INC. | $146.25 | 2019-2025 | |
| Tolmar, INC. | $98.48 | 2023-2025 | Eligard, Jatenzo |
| Merck Sharp & Dohme LLC | $77.50 | 2019-2025 | Keytruda, Lynparza |
| Intuitive Surgical, INC. | $72.07 | 2020 | |
| Baxter Healthcare | $64.33 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $58.38 | 2022-2023 | N.A. |
| Allergan, INC. | $56.98 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.93 | 2024 | Lynparza |
| Urovant Sciences INC | $43.37 | 2022 | |
| Boston Scientific Corporation | $38.70 | 2019-2020 | |
| Axonics, INC. | $36.45 | 2023 | Bulkamid, Axonics |
| Myovant Sciences INC. | $31.74 | 2021-2022 | |
| Photocure INC | $30.28 | 2020-2022 | |
| Procept Biorobotics Corporation | $19.58 | 2022 | |
| Dendreon Pharmaceuticals LLC | $18.64 | 2019 | |
| Sanofi Pasteur INC. | $16.67 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.56 | 2023 | Oxlumo |
| Olympus America INC. | $15.78 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $15.49 | 2021 | |
| Dentsply Ih INC. | $15.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.17 | 2025 | |
| Avadel Specialty Pharmaceuticals, LLC | $14.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.